Literature DB >> 9139965

Effects of relaxin on rat atrial myocytes. II. Increased calcium influx derived from action potential prolongation.

E S Piedras-Rentería1, O D Sherwood, P M Best.   

Abstract

Relaxin produces positive inotropic and chronotropic effects in rat hearts. The effect of relaxin on the action potential duration (APD) of single quiescent rat atrial cells was investigated with a whole cell patch clamp. Relaxin induced a significant, dose-dependent prolongation of the APD. This effect was maximal at 200 ng/ml (nominal concentration of 33.6 nM), which caused, on average, a 57% increase in the time taken to reach 90% repolarization. The effect of relaxin was blocked by the protein kinase A inhibitor 5-24 amide, indicating that its effect is mediated by an adenosine 3',5'-cyclic monophosphate-dependent mechanism. The increased APD induced by relaxin caused an enhanced entrance of calcium, with the charge carried through voltage-activated calcium channels increased by approximately 25%. This increase was not due to a direct modulation of calcium currents (20); rather, it was a consequence of the longer period of cellular depolarization. Our findings that relaxin increased the APD and therefore increased the calcium influx in atrial myocytes could explain the positive inotropic effects induced by relaxin in atrial preparations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9139965     DOI: 10.1152/ajpheart.1997.272.4.H1798

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  6 in total

Review 1.  Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation.

Authors:  Michelle L Halls
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin.

Authors:  Andrew R Kompa; Chrishan S Samuel; Roger J Summers
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

3.  Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts.

Authors:  Ashish Parikh; Divyang Patel; Charles F McTiernan; Wenyu Xiang; Jamie Haney; Lei Yang; Bo Lin; Aaron D Kaplan; Glenna C L Bett; Randall L Rasmusson; Sanjeev G Shroff; David Schwartzman; Guy Salama
Journal:  Circ Res       Date:  2013-06-07       Impact factor: 17.367

Review 4.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

5.  Ligand-activated RXFP1 gene therapy ameliorates pressure overload-induced cardiac dysfunction.

Authors:  Nuttarak Sasipong; Philipp Schlegel; Julia Wingert; Christoph Lederer; Eric Meinhardt; Amelie Ziefer; Constanze Schmidt; Kleopatra Rapti; Cornelia Thöni; Norbert Frey; Patrick Most; Hugo A Katus; Philip W J Raake
Journal:  Mol Ther       Date:  2021-04-09       Impact factor: 12.910

6.  Relaxin Inhibits the Cardiac Myofibroblast NLRP3 Inflammasome as Part of Its Anti-Fibrotic Actions via the Angiotensin Type 2 and ATP (P2X7) Receptors.

Authors:  Felipe Tapia Cáceres; Tracey A Gaspari; Mohammed Akhter Hossain; Chrishan S Samuel
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.